
Johnson & Johnson has submitted an sNDA to the FDA for Caplyta for the treatment of bipolar mania.
Expiring on May 20, 2024, this CME discusses how to apply several novel treatment approaches in the treatment of patients with bipolar depression. Here are 5 key takeaways.


